




RealRate

PHARMACEUTICAL 2025

Hepion Pharmaceuticals Inc
Rank 220 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 3.5% points. The greatest weakness of Hepion Pharmaceuticals Inc is the variable Assets, reducing the Economic Capital Ratio by 191% points.

The company's Economic Capital Ratio, given in the ranking table, is 3.6%, being 211% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	1,614
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,144
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	87
Other Expenses	198
Other Liabilities	333
Other Net Income	6,352
Other Revenues	0
Property and Equipment	0
Research and Development	11,847
Selling, General and Administrative Expense	7,499

Output Variable	Value in 1000 USD
Assets	1,614
Liabilities	3,477
Expenses	19,544
Revenues	0
Stockholders Equity	-1,863
Net Income	-13,192
Comprehensive Net Income	-13,149
BaseVar	15,537
ECR before LimitedLiability	-676%
Economic Capital Ratio	3.6%